Cell recognitive bioadhesive-based osteogenic barrier coating with localized delivery of bone morphogenetic protein-2 for accelerated guided bone regeneration

by Selleckchem | Jul 11 2023

Titanium mesh (Ti-mesh) for guided bone regeneration (GBR) approaches has been extensively considered to offer space maintenance in reconstructing the alveolar ridge within bone defects due to its superb mechanical properties and biocompatibility. However, soft tissue invasion across the pores of the Ti-mesh and intrinsically limited bioactivity of the titanium substrates often hinder satisfactory clinical outcomes in GBR treatments. Here, a cell recognitive osteogenic barrier coating was proposed using a bioengineered mussel adhesive protein (MAP) fused with Alg-Gly-Asp (RGD) peptide to achieve highly accelerated bone regeneration. The fusion bioadhesive MAP-RGD exhibited outstanding performance as a bioactive physical barrier that enabled effective cell occlusion and a prolonged, localized delivery of bone morphogenetic protein-2 (BMP-2). The MAP-RGD@BMP-2 coating promoted in vitro cellular behaviors and osteogenic commitments of mesenchymal stem cells (MSCs) via the synergistic crosstalk effects of the RGD peptide and BMP-2 in a surface-bound manner. The facile gluing of MAP-RGD@BMP-2 onto the Ti-mesh led to a distinguishable acceleration of the in vivo formation of new bone in terms of quantity and maturity in a rat calvarial defect. Hence, our protein-based cell recognitive osteogenic barrier coating can be an excellent therapeutic platform to improve the clinical predictability of GBR treatment.

Comments:

The passage describes a novel approach for guided bone regeneration (GBR) using a titanium mesh (Ti-mesh) coated with a bioengineered mussel adhesive protein (MAP) fused with an Alg-Gly-Asp (RGD) peptide. This coating aims to overcome the limitations of Ti-mesh by preventing soft tissue invasion and enhancing the bioactivity of the titanium substrate, thereby promoting accelerated bone regeneration.

The fusion bioadhesive MAP-RGD coating serves as a bioactive physical barrier that effectively blocks the infiltration of soft tissue and allows for localized delivery of bone morphogenetic protein-2 (BMP-2). BMP-2 is a growth factor known for its osteogenic properties, which can stimulate the formation of new bone. The MAP-RGD@BMP-2 coating demonstrated excellent performance in vitro by promoting cellular behaviors and osteogenic commitments of mesenchymal stem cells (MSCs). This effect is achieved through the synergistic crosstalk between the RGD peptide and BMP-2 when presented in a surface-bound manner.

The authors further tested the MAP-RGD@BMP-2 coating in vivo using a rat calvarial defect model. The results showed that the coating, when applied to the Ti-mesh, significantly accelerated the formation of new bone in terms of both quantity and maturity.

In summary, the protein-based cell recognitive osteogenic barrier coating described in the passage offers a promising therapeutic platform for enhancing the clinical predictability of GBR treatment. By addressing the challenges associated with Ti-mesh, such as soft tissue invasion and limited bioactivity, this approach may lead to improved outcomes in reconstructing alveolar ridges and bone defects.